Immix Biopharma, Inc. Common Stock (IMMX) is a publicly traded Healthcare sector company. As of September 16, 2026, IMMX trades at $12.24 with a market cap of $873.50M and a P/E ratio of -13.62. IMMX moved +0.82% today. Year to date, IMMX is +132.12%; over the trailing twelve months it is +480.86%. Its 52-week range spans $1.34 to $15.10. Analyst consensus is strong buy with an average price target of $21.20. Rallies surfaces IMMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest IMMX news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $12.24 |
| Market Cap | $873.50M |
| P/E Ratio | -13.62 |
| EPS | $-0.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.10 |
| 52-Week Low | $1.34 |
| Volume | 60 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-29.44M |
| Gross Margin | 0.00% |
6 analysts cover IMMX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.20.